Bernstein maintains Eli Lilly stock Outperform, $1,100 target
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Kyodo News on MSN8h
U.S. regulator OKs Eisai-Biogen Alzheimer's drug's continuous dosing
Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the ...